PDCD1 and head and neck squamous cell carcinoma: Indeed, 50% of locally advanced and metastatic cSCC patients and 65% of recurrent and metastatic (R/M) HNSCC patients remain unresponsive or develop acquired resistance to anti-PD-1 therapy6,7,48–50.